RNA-based Therapeutics and Vaccine Market
RNA-based Therapeutics and Vaccine Market Study by Therapeutics and Vaccines for Oncology, Immunology, Ophthalmology, and Cardiovascular, Infectious, and Genetic Diseases from 2024 to 2034
Analysis of RNA-based Therapeutics and Vaccine Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
RNA-based Therapeutics and Vaccine Market Outlook (2024 to 2034)
Valuation of the global RNA-based therapeutics and vaccine market is evaluated to increase from US$ 180.5 million in 2024 to US$ 1.24 billion by the end of 2034. Revenue in the market has been forecasted to rise at a remarkable CAGR of 21.3% from 2024 to 2034.
As the medical industry progresses, the market for RNA-based therapeutics and vaccines is likely to attract more attention, with an increasing number of doctors and scientists investing their efforts to harness its benefits.
RNA-based therapeutics have sparked significant discussion due to their immense potential in treating chronic diseases. Moreover, RNA immunizations offer advantages over gene delivery in terms of effectiveness, manufacturing, and distribution. These qualities are encouraging more doctors to adopt this therapy, contributing to RNA-based therapeutics and vaccine market growth.
Since mRNA treatments and immunizations have demonstrated promise in human clinical trials, demand for them has surged. In addition, the success of COVID-19 vaccines by Moderna and Pfizer-BioNTech has led to a marked increase in the exploration of protein expression vaccine therapies in cancer clinical research.
Key Market Growth Drivers
- RNA aptamers are used to inhibit a specific protein from binding to its cell membrane receptor or to obstruct a protein's activity by attaching to its target.
- They offer an excellent alternative to traditional drugs, effectively treating diseases and gaining popularity among individuals seeking novel treatments beyond conventional medicines.
- A diverse range of diseases, including genetic disorders, viral infections, cancer, neurodivergent conditions, and cardiovascular diseases, are being treated with RNA-based therapeutics.
| Report Attribute | Detail |
|---|---|
| RNA-based therapeutics and Vaccine Market Size (2024E) | US$ 180.5 Million |
| Forecasted Market Value (2034F) | US$ 1.24 Billion |
| Global Market Growth Rate (2024 to 2034) | 21.3% CAGR |
| Canada Market Growth Rate (2024 to 2034) | 19.5% CAGR |
| China Market Value (2034F) | US$ 56 Million |
| North America Market Share (2024E) | 42.6% |
| East Asia Market Share (2034F) | 11.5% |
| Key Companies Profiled | Alnylam Pharmaceuticals Inc.; Arbutus Biopharma Corp.; Arrowhead Pharmaceuticals Inc.; BioNTech AG; Dicerna Pharmaceuticals Inc; Regulus Therapeutics Inc.; Marina Biotech Inc.; Moderna Therapeutics Inc.; Santaris Pharma A/S. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Key Developments are Benefitting Companies in This Market?
“Growing Emphasis on Developing Advanced Treatments for Rare and Chronic Illnesses”
RNA-based biopharmaceuticals, often called RNA-based therapies and vaccines, are viewed as advanced treatments and preventatives for various rare and chronic illnesses, including cancer, tuberculosis, diabetes, and cardiovascular disorders.
- On March 5, 2024, the FDA approved the first cancer TIL therapy for advanced melanoma, which is meant to ease the process for oncologists.
- June 2024 saw the introduction of RNA Direct Injection, a novel approach to cancer treatment, immune system impairment, and gene therapy, transforming the oncology sector.
“Increasing Adoption of RNA Interference, Antisense, and Smart Technologies”
RNA therapies and vaccines are unique in that they offer superior stability when compared to other treatments. When it comes to treating obstinate problems, they are becoming more and more popular, even if the bulk of them are still in trials as previously indicated.
Technologies that are being quickly embraced are RNA interference, antisense, and smart technologies. These are major RNA-based therapeutics and vaccine market trends that players are leveraging. Researchers have been focusing on RNAi and antisense technologies because they aid in providing the base sequence needed to produce RNA medicines. It should not be assumed that both technologies operate in the same way, though. Whereas RNAi technology entails the destruction of certain mRNA molecules, antisense technology creates an RNA strand from a known gene sequence.
“Focused Research Collaborations on Rare Genetic Diseases”
Several market collaborations are strengthening the market by allowing new players to enter, establish their positions, invest their knowledge, and stimulate growth.
- In January 2022, Pfizer Inc. and Beam Therapeutics Inc. entered a four-year exclusive research collaboration focused on in vivo base editing programs targeting three rare genetic diseases affecting the liver, muscle, and central nervous system.
What are the Factors Limiting Market Opportunities for Companies?
“Recalls or Discontinuation of RNA-Based Therapeutics Products Affecting Trust”
Recalls or discontinuations can occur due to various reasons, such as unexpected side effects, safety concerns, efficacy issues, or noncompliance with regulations. These events can undermine trust in RNA therapeutic products among consumers and healthcare professionals, leading to reduced adoption and demand.
Withdrawals or recalls can affect the reputation of involved firms and public perception of RNA therapies as promising treatment options. Investors may also become cautious and reduce their support for research and development in the sector. Regulatory authorities may tighten rules, resulting in more stringent approval processes. All of these factors are impeding the expansion of the RNA-based therapeutics and vaccine market size.
“High Immunogenicity of Exogenous RNA Hindering Therapeutic Application”
Exogenous RNA is rapidly degraded by ubiquitous RNases in tissues and the environment when it is highly immunogenic. There are several obstacles in the way of RNA therapies' advancement, which has made creative methods for their development and production necessary.
One of the main challenges is the intrinsic vulnerability of foreign RNA to fast destruction by omnipresent RNases found in tissues and the environment. Effectively delivering negatively charged RNA molecules through hydrophobic cytoplasmic membranes of target cells is another crucial challenge. Additionally, a significant barrier to overcome is the cell toxicity and hindrance to RNA translation into therapeutic proteins due to the high immunogenicity of exogenous RNA.
“Substantial Research Costs Associated with RNA-Based Therapies”
The market for RNA-based vaccines and treatments is susceptible to high research costs and a higher failure rate in clinical trials. Additionally, challenges in medication distribution cannot be overlooked. The rising costs of research may compel developing economies to reassess their participation in this field.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Analysis
The South Korea market is calculated to expand at a remarkable CAGR of 22.3% from 2024 to 2034. The country is set to occupy an RNA-based therapeutics and vaccine market share of 24.7% in East Asia by the end of 2034.
Why Does the United States Hold a Leading Position in the Global Market?
“Focus on Healthcare Advancements and Rising Government Investments in RNA-Based Technology”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 69 Million |
| Growth Rate (2024 to 2034) | 19.8% CAGR |
| Projected Value (2034F) | US$ 418 Million |
The United States holds a leading position in the global market. This is attributed to technological advancements and the increasing incidence of chronic diseases. Moreover, the government is investing significantly in research to advance RNA-based technology.
- To learn more about the functioning of RNA particles, Rochester and Albany established a new Center of Excellence in RNA research on May 10, 2024.
- To better understand the untapped potential of ribonucleic acid (RNA) for potentially far-reaching biotechnology applications, from disease prevention in crops to cancer-fighting therapies, the U.S. National Science Foundation awarded over US$ 12.7 million in February 2024 to nine research teams. Through the Molecular Foundations for Biotechnology (MFB) initiative, which is a collaborative endeavor between NSF and the National Human Genome Research Institute (NHGRI) of the National Institutes of Health, the nine teams will each receive US$ 1 million to US$ 1.65 million from NSF.
What Makes China a Lucrative Market for RNA-based Therapeutics Providers?
“Focus on Research into Single-stranded Nucleic Acid”
| Attribute | China |
|---|---|
| Market Value (2024E) | US$ 7 Million |
| Growth Rate (2024 to 2034) | 23.7% CAGR |
| Projected Value (2034F) | US$ 56 Million |
Single-stranded nucleic acid molecules known as RNA aptamers have a high degree of selectivity and affinity when binding to particular targets. Numerous therapeutic uses, such as those for infectious disorders, heart conditions, and cancer, have been studied. One significant area of market opportunity is the advancement in the creation of medicines based on RNA aptamer technology. This is due to the several potential benefits that RNA aptamers offer over conventional medication therapy.
- The modular gene-editing system known as CyDENT was disclosed by researchers at the Chinese Academy of Sciences Institute of Genetics and Developmental Biology in the journal Nature Biotechnology on August 28.
- On March 22, 2023, Chinese authorities authorized the first mRNA vaccine produced domestically by pharmaceutical company CSPC.
Category-wise Evaluation
Based on indication, genetic diseases are projected to account for 59% share of overall revenue by 2034.
Why Do RNA-Based Therapeutics Hold a Larger Market Share Compared to Vaccines?
“Commitment of Researchers to Innovation in RNA-based Therapeutics Due to Their Efficacy”
| Attribute | RNA-based Therapeutics |
|---|---|
| Segment Value (2024E) | US$ 180.5 Million |
| Growth Rate (2024 to 2034) | 20% CAGR |
| Projected Value (2034F) | US$ 1.12 Billion |
Among RNA-based therapeutics and vaccines, the therapeutics segment is expected to capture a larger market share in 2024 due to its significant influence on addressing several diseases. Doctors are dedicating their time to developing and advancing innovations in this field.
Why are Doctors and Scientists Focusing on RNA-Based Techniques in Genetic Disease Research?
“RNA-based Techniques Facilitating Speedy Exploration of Treatments for Genetic Diseases”
| Attribute | Genetic Diseases |
|---|---|
| Segment Value (2024E) | US$ 136.7 Million |
| Growth Rate (2024 to 2034) | 18.2% CAGR |
| Projected Value (2034F) | US$ 730.6 Million |
RNA-based therapeutics effectively assess the body's condition and provide precise results that can be utilized for medical examinations. Increasingly, doctors and scientists are choosing this method to swiftly explore treatments for genetic diseases.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Market Rivalry
Key players in the RNA-based therapeutics and vaccine market are pursuing every avenue of growth, including joint ventures, partnerships, the introduction of new medications and vaccines, acquisitions, mergers, and other means to stay ahead of the competition. They are adapting to evolving market trends such as focusing on peptide-based infection therapeutics, arthritis therapeutics, and osteoporosis therapeutics.
- Acuitas Medicines and Pfizer signed a 'development and option agreement' on January 10, 2022, allowing Pfizer to license the latter's LNP technology for nearly ten targets for the development of medicines or vaccines. This would be provided without restriction.
Fact.MR provides detailed information about the price points of key RNA-based therapeutics and vaccine providers positioned across the world, sales growth, production capacity, and speculative technological expansion, in this new market report.
Key Segments of RNA-based Therapeutics and Vaccine Market Research
-
By Product Type :
- RNA-based Therapeutics
- RNA-based Vaccines (mRNA)
-
By Indication :
- Oncology
- Immunology
- Ophthalmology
- Cardiovascular Diseases
- Infectious Diseases
- Genetic Diseases
- Others
-
By Region :
- North America
- Latin America
- Eastern Europe
- Western Europe
- East Asia
- South Asia & Pacific
- Middle East & Africa
Table of Content
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 6.1. Product Type 6.2. Indication 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Product Type 7.1. RNA-based Therapeutics 7.2. RNA-based Vaccines (mRNA) 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Indication 8.1. Oncology 8.2. Immunology 8.3. Ophthalmology 8.4. Cardiovascular Diseases 8.5. Infectious Diseases 8.6. Genetic Diseases 8.7. Others 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 9.1. North America 9.2. Latin America 9.3. Western Europe 9.4. Eastern Europe 9.5. East Asia 9.6. South Asia & Pacific 9.7. Middle East & Africa 10. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 11. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 12. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Sales Forecast 2024 to 2034 by Product Type, Indication, and Region for 30 Countries 18. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 19. Company Profile 19.1. Alnylam Pharmaceuticals Inc. 19.2. Arbutus Biopharma Corp. 19.3. Arrowhead Pharmaceuticals Inc. 19.4. BioNTech AG 19.5. Dicerna Pharmaceuticals Inc 19.6. Regulus Therapeutics Inc. 19.7. Marina Biotech Inc. 19.8. Moderna Therapeutics Inc. 19.9. Santaris Pharma A/S 20. Assumptions and Acronyms Used 21. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Analysis, by Product Type, 2019 to 2023
Table 02: Global Market Value (US$ Mn) Analysis, by Product Type, 2024 to 2034
Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Product Type, 2024 to 2034
Table 04: Global Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 05: Global Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 06: Global Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 07: Global Market Value (US$ Mn) Analysis, by Region, 2019 to 2023
Table 08: Global Market Value (US$ Mn) Analysis, by Region, 2024 to 2034
Table 09: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2024 to 2034
Table 10: North America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 11: North America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 12: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 13: North America Market Value (US$ Mn) Analysis, by Product Type, 2019 to 2023
Table 14: North America Market Value (US$ Mn) Analysis, by Product Type, 2024 to 2034
Table 15: North America Market Value (US$ Mn) Opportunity Analysis, by Product Type, 2024 to 2034
Table 16: North America Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 17: North America Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 18: North America Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 19: Latin America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 20: Latin America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 21: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 22: Latin America Market Value (US$ Mn) Analysis, by Product Type, 2019 to 2023
Table 23: Latin America Market Value (US$ Mn) Analysis, by Product Type, 2024 to 2034
Table 24: Latin America Market Value (US$ Mn) Opportunity Analysis, by Product Type, 2024 to 2034
Table 25: Latin America Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 26: Latin America Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 27: Latin America Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 28: Western Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 29: Western Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 30: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 31: Western Europe Market Value (US$ Mn) Analysis, by Product Type, 2019 to 2023
Table 32: Western Europe Market Value (US$ Mn) Analysis, by Product Type, 2024 to 2034
Table 33: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Product Type, 2024 to 2034
Table 34: Western Europe Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 35: Western Europe Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 36: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 37: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 38: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 39: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 40: Eastern Europe Market Value (US$ Mn) Analysis, by Product Type, 2019 to 2023
Table 41: Eastern Europe Market Value (US$ Mn) Analysis, by Product Type, 2024 to 2034
Table 42: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Product Type, 2024 to 2034
Table 43: Eastern Europe Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 44: Eastern Europe Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 45: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 46: East Asia Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 47: East Asia Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 48: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 49: East Asia Market Value (US$ Mn) Analysis, by Product Type, 2019 to 2023
Table 50: East Asia Market Value (US$ Mn) Analysis, by Product Type, 2024 to 2034
Table 51: East Asia Market Value (US$ Mn) Opportunity Analysis, by Product Type, 2024 to 2034
Table 52: East Asia Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 53: East Asia Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 54: East Asia Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 55: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 56: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 57: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 58: South Asia & Pacific Market Value (US$ Mn) Analysis, by Product Type, 2019 to 2023
Table 59: South Asia & Pacific Market Value (US$ Mn) Analysis, by Product Type, 2024 to 2034
Table 60: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Product Type, 2024 to 2034
Table 61: South Asia & Pacific Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 62: South Asia & Pacific Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 63: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 64: MEA Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 65: MEA Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 66: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 67: MEA Market Value (US$ Mn) Analysis, by Product Type, 2019 to 2023
Table 68: MEA Market Value (US$ Mn) Analysis, by Product Type, 2024 to 2034
Table 69: MEA Market Value (US$ Mn) Opportunity Analysis, by Product Type, 2024 to 2034
Table 70: MEA Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 71: MEA Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 72: MEA Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 04: Global Market Incremental $ Opportunity, 2024 to 2034
Figure 05: Global Market Share and BPS Analysis by Product Type, 2024 & 2034
Figure 06: Global Market Y-o-Y Growth Projections by Product Type, 2024 to 2034
Figure 07: Global Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 08: Global Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 09: Global Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 10: Global Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 11: Global Market Share and BPS Analysis by Region, 2024 & 2034
Figure 12: Global Market Y-o-Y Growth Projections by Region, 2024 to 2034
Figure 13: Global Market Attractiveness Analysis by Region, 2024 to 2034
Figure 14: North America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 15: North America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 16: North America Market Value Y-o-Y Growth and Forecast, 2034
Figure 17: North America Market Incremental $ Opportunity, 2024 to 2034
Figure 18: North America Market Share Analysis by Country, 2024 & 2034
Figure 19: North America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 20: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 21: North America Market Share and BPS Analysis by Product Type, 2024 & 2034
Figure 22: North America Market Y-o-Y Growth Projections by Product Type, 2024 to 2034
Figure 23: North America Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 24: North America Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 25: North America Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 26: North America Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 27: Latin America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 28: Latin America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 29: Latin America Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 30: Latin America Market Incremental $ Opportunity, 2024 to 2034
Figure 31: Latin America Market Share Analysis by Country, 2024 & 2034
Figure 32: Latin America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 33: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 34: Latin America Market Share and BPS Analysis by Product Type, 2024 & 2034
Figure 35: Latin America Market Y-o-Y Growth Projections by Product Type, 2024 to 2034
Figure 36: Latin America Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 37: Latin America Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 38: Latin America Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 39: Latin America Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 40: Western Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 41: Western Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 42: Western Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 43: Western Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 44: Western Europe Market Share Analysis by Country, 2024 & 2034
Figure 45: Western Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 46: Western Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 47: Western Europe Market Share and BPS Analysis by Product Type, 2024 & 2034
Figure 48: Western Europe Market Y-o-Y Growth Projections by Product Type, 2024 to 2034
Figure 49: Western Europe Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 50: Western Europe Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 51: Western Europe Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 52: Western Europe Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 53: Eastern Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 54: Eastern Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 55: Eastern Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 56: Eastern Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 57: Eastern Europe Market Share Analysis by Country, 2024 & 2034
Figure 58: Eastern Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 59: Eastern Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 60: Eastern Europe Market Share and BPS Analysis by Product Type, 2024 & 2034
Figure 61: Eastern Europe Market Y-o-Y Growth Projections by Product Type, 2024 to 2034
Figure 62: Eastern Europe Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 63: Eastern Europe Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 64: Eastern Europe Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 65: Eastern Europe Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 66: East Asia Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 67: East Asia Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 68: East Asia Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 69: East Asia Market Incremental $ Opportunity, 2024 to 2034
Figure 70: East Asia Market Share Analysis by Country, 2024 & 2034
Figure 71: East Asia Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 72: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 73: East Asia Market Share and BPS Analysis by Product Type, 2024 & 2034
Figure 74: East Asia Market Y-o-Y Growth Projections by Product Type, 2024 to 2034
Figure 75: East Asia Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 76: East Asia Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 77: East Asia Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 78: East Asia Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 79: South Asia & Pacific Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 80: South Asia & Pacific Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 81: South Asia & Pacific Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 82: South Asia & Pacific Market Incremental $ Opportunity, 2024 to 2034
Figure 83: South Asia & Pacific Market Share Analysis by Country, 2024 & 2034
Figure 84: South Asia & Pacific Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 85: South Asia & Pacific Market Attractiveness Analysis by Country, 2024 to 2034
Figure 86: South Asia & Pacific Market Share and BPS Analysis by Product Type, 2024 & 2034
Figure 87: South Asia & Pacific Market Y-o-Y Growth Projections by Product Type, 2024 to 2034
Figure 88: South Asia & Pacific Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 89: South Asia & Pacific Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 90: South Asia & Pacific Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 91: South Asia & Pacific Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 92: MEA Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 93: MEA Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 94: MEA Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 95: MEA Market Incremental $ Opportunity, 2024 to 2034
Figure 96: MEA Market Share Analysis by Country, 2024 & 2034
Figure 97: MEA Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 98: MEA Market Attractiveness Analysis by Country, 2024 to 2034
Figure 99: MEA Market Share and BPS Analysis by Product Type, 2024 & 2034
Figure 100: MEA Market Y-o-Y Growth Projections by Product Type, 2024 to 2034
Figure 101: MEA Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 102: MEA Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 103: MEA Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 104: MEA Market Attractiveness Analysis by Indication, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the RNA-based therapeutics and vaccine market in 2024?
The global RNA-based therapeutics and vaccine market is estimated at US$ 180.5 million in 2024.
What are the projected sales of RNA-based therapeutics and vaccines by 2034?
Worldwide sales of RNA-based therapeutics and vaccines are forecasted to reach US$ 1.24 billion by the end of 2034.
What is the demand growth outlook for the genetic disease segment?
Demand for vaccines for genetic diseases is calculated to increase at a CAGR of 18.2% from 2024 to 2034.
Which is a key market for RNA-based therapeutics and vaccine suppliers?
China is expected to reach a market value of US$ 56 million by 2034.
What is the scenario for the market in Japan?
The market in Japan is forecasted to be valued at US$ 8 million in 2024.
Which indication accounts for an important share globally?
Cardiovascular diseases are set to hold a market share of 9.5% with the segment valued at US$ 17.2 million in 2024.
Who are the top companies in this market?
Alnylam Pharmaceuticals Inc., Arbutus Biopharma Corp, and Arrowhead are key players in this market.
RNA-based Therapeutics and Vaccine Market